We are live on ! Find out more
ARCT icon

Arcturus Therapeutics
ARCT

135 hedge funds and large institutions have $865M invested in Arcturus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 33

28% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 32

26% more call options, than puts

Call options by funds: $46.9M | Put options by funds: $37.1M

10% more capital invested

Capital invested by funds: $783M → $865M (+$81.7M)

6% more funds holding

Funds holding: 127 → 135 (+8)

2.24% more ownership

Funds ownership: 74.68% → 76.92% (+2.2%)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
135
Holders Change
+8
Holders Change %
+6.3%
% of All Funds
2.39%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
41
Increased
54
Reduced
33
Closed
32
Calls
$46.9M
Puts
$37.1M
Net Calls
+$9.71M
Net Calls Change
-$859K

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$141M
2
AIM
ARK Investment Management
Florida
+$99.1M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$48.7M
4
O
OrbiMed
New York
+$44.8M
5
BlackRock
BlackRock
New York
+$42M

Top Sellers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
-$68.4M
2
State Street
State Street
Massachusetts
-$37.1M
3
CAM
Cormorant Asset Management
Massachusetts
-$30M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$20.7M
5
EARNEST Partners
EARNEST Partners
Georgia
-$20.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
151
Cubist Systematic Strategies
Connecticut
– -$427K -9,962 Closed
SM
152
SG3 Management
Puerto Rico
– -$416K -9,697 Closed
Invesco
153
Invesco
Georgia
– -$362K -8,414 Closed
E
154
Ergoteles
New York
– -$344K -8,020 Closed
Marshall Wace
155
Marshall Wace
United Kingdom
– -$330K -7,689 Closed
VRS
156
Virginia Retirement Systems
Virginia
– -$309K -7,200 Closed
BAM
157
Blueshift Asset Management
New Jersey
– -$278K -6,477 Closed
PCM
158
Prelude Capital Management
New York
– -$388K -5,727 Closed
JCM
159
JS Capital Management
New York
– -$245K -5,700 Closed
AGM
160
Alpine Global Management
New York
– -$212K -4,940 Closed
TCM
161
Traynor Capital Management
Pennsylvania
– -$243K -4,939 Closed
MAM
162
Meeder Asset Management
Ohio
– -$207K -4,830 Closed
PHK
163
Point72 Hong Kong
Hong Kong
– -$98K -2,281 Closed
SAM
164
Shell Asset Management
Netherlands
– -$65K -1,510 Closed
PMFA
165
Plante Moran Financial Advisors
Michigan
– -$43K -1,000 Closed
EI
166
Ellevest Inc
New York
– -$1K -30 Closed
Rockefeller Capital Management
167
Rockefeller Capital Management
New York
– +$339 +5 New
3 4 5 6
7

ARCT Hedge Fund Activity: Q4 2020 in Review

135 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2020, worth a combined $865M — up 10% from $783M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new ARCT positions and 32 closed out — a net gain of 9 holders — while 54 added to existing stakes and 33 trimmed.

The largest buyer was Federated Hermes, adding an estimated $141M. The largest seller was HealthCor Management, exiting entirely with an estimated $68.4M sold.

  • 135 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2020, up from 127 in Q3 2020.
  • Funds reported $865M of Arcturus Therapeutics stock for Q4 2020, up 10% quarter-over-quarter.
  • 41 funds opened new Arcturus Therapeutics positions in Q4 2020 and 32 closed out, a net change of +9 holders.
  • The largest Arcturus Therapeutics buyer in Q4 2020 was Federated Hermes, an estimated $141M added.
  • The largest Arcturus Therapeutics seller in Q4 2020 was HealthCor Management, an estimated $68.4M sold.

Based on aggregated 13F filings for Q4 2020.